GO:0032384 negative regulation of intracellular cholesterol transport: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032384 describes any process that stops, prevents, or reduces the directed movement of cholesterol within cells, as defined by QuickGO.
• Active cholesterol in the plasma membrane is a key signal that coordinates feedback control of cellular cholesterol homeostasis.
• GRAMD1C is a cholesterol transport protein that regulates autophagosome biogenesis and mitochondrial bioenergetics, linking cholesterol transport to autophagy.
• START domain proteins mediate intracellular cholesterol trafficking in steroidogenic cells and are targets of negative regulation.
• Phosphatidylcholine availability influences the cholesterol transport machinery, adding a lipid-composition layer of control.
• SREBP activation is a sterol-sensitive transcriptional program that responds to changes in intracellular cholesterol distribution.
Description
GO:0032384, negative regulation of intracellular cholesterol transport, is a biological process ontology term that captures any mechanism which stops, prevents, or reduces the frequency, rate, or extent of the directed movement of cholesterol within cells. Cholesterol is not merely a structural lipid; its distribution among the plasma membrane, endoplasmic reticulum, mitochondria, and endocytic compartments determines membrane order, signal transduction, and organelle function. Consequently, cells have evolved multiple layers of negative regulation to prevent inappropriate cholesterol accumulation or depletion in specific compartments.
negative regulation of intracellular cholesterol transport At A Glance
| GO ID | GO:0032384 |
|---|---|
| GO term | negative regulation of intracellular cholesterol transport |
| Ontology | biological_process |
| Synonym | down regulation of intracellular cholesterol transport; down-regulation of intracellular cholesterol transport; downregulation of intracellular cholesterol transport; inhibition of intracellular cholesterol transport |
| Major function | Restricts or slows the directed movement of cholesterol between intracellular membranes and organelles |
| Related transport proteins | GRAMD1C, START domain proteins, annexins, caveolae-associated proteins |
| Related regulatory lipids | Active cholesterol, phosphatidylcholine, sterol intermediates |
| Related signaling | SREBP activation, autophagy initiation, mitochondrial bioenergetics |
What Is GO:0032384?
In practical terms, GO:0032384 refers to the set of cellular processes that put the brakes on cholesterol movement inside a cell. This includes reducing the transfer of cholesterol between membranes, limiting its delivery to mitochondria or other organelles, and dampening the activity of transport proteins and lipid-transfer modules that would otherwise move cholesterol. The QuickGO definition emphasizes any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of cholesterol within cells.
Why Is negative regulation of intracellular cholesterol transport Important in Cell Biology?
Understanding negative regulation of intracellular cholesterol transport is important because cholesterol misdistribution is a common feature of metabolic, cardiovascular, and neurodegenerative disease. The transport protein GRAMD1C regulates autophagy initiation and mitochondrial bioenergetics, showing that negative control of cholesterol movement is directly coupled to organelle quality control. Active cholesterol at the plasma membrane coordinates cell cholesterol homeostasis, and disrupting this feedback can alter membrane signaling and lipid storage. START domain proteins control steroidogenic cholesterol trafficking, and their dysregulation affects hormone production. Phosphatidylcholine availability further tunes the cholesterol transport machinery, linking phospholipid metabolism to sterol distribution.
• Maintains cholesterol distribution among plasma membrane, ER, mitochondria, and endosomes.
• Prevents excessive cholesterol delivery to mitochondria, which can stress the organelle.
• Supports autophagy initiation by controlling autophagosome biogenesis through GRAMD1C.
• Regulates steroid hormone synthesis by limiting cholesterol access to steroidogenic enzymes.
• Couples cholesterol transport to SREBP-mediated transcriptional feedback.
• Influences caveolae-dependent signaling, including eNOS regulation.
• Depends on phosphatidylcholine availability for normal transport machinery function.
• Annexins contribute to mitochondrial cholesterol-related processes and membrane dynamics.
• Relevant to cancer, neurodegeneration, and metabolic disease research.
• Provides targets for CRISPR knockout, knock-in, and overexpression studies.
What Happens During negative regulation of intracellular cholesterol transport?
Sensing active cholesterol at the plasma membrane
In simple terms: The cell checks how much cholesterol is available and active at its surface.
Active cholesterol in the plasma membrane acts as a signal that coordinates cell cholesterol homeostasis. When active cholesterol levels rise, feedback pathways reduce further cholesterol movement and storage, preventing overload of intracellular membranes.
Restricting cholesterol transfer to mitochondria
In simple terms: The cell limits how much cholesterol reaches mitochondria.
GRAMD1C is a cholesterol transport protein that regulates autophagosome biogenesis and mitochondrial bioenergetics. Negative regulation of cholesterol transport toward mitochondria helps maintain mitochondrial function and prevents lipid-induced stress.
Gating START domain-mediated trafficking
In simple terms: Specialized carrier proteins can be slowed down to control cholesterol delivery.
START domain proteins mediate the intracellular trafficking of cholesterol in steroidogenic cells. Negative regulation of these carriers reduces cholesterol delivery to steroidogenic enzymes and modulates hormone synthesis.
Coupling to SREBP transcriptional feedback
In simple terms: When cholesterol movement is restricted, the cell adjusts gene expression.
Sterol metabolism and SREBP activation are tightly linked. Changes in intracellular cholesterol distribution influence SREBP processing, which in turn adjusts expression of cholesterol synthesis and uptake genes, forming a feedback loop that can reinforce negative regulation of transport.
Lipid environment and membrane composition
In simple terms: The lipid surroundings of transport proteins affect how fast cholesterol moves.
Phosphatidylcholine availability influences the cholesterol transport machinery. Altering phosphatidylcholine levels can change membrane properties and the efficiency of cholesterol transfer, thereby contributing to negative regulation of intracellular cholesterol transport.
Annexins and membrane contact sites
In simple terms: Annexin proteins help organize membrane contacts where cholesterol moves.
Annexins are present in mitochondria and participate in membrane-related processes. Their involvement in mitochondrial membrane dynamics may intersect with cholesterol transport regulation, although the precise negative regulatory roles require further study.
Key Genes Involved in GO:0032384 negative regulation of intracellular cholesterol transport
The following genes and proteins have been implicated in cholesterol transport and its negative regulation, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GRAMD1C | Cholesterol transport protein regulating autophagy initiation and mitochondrial bioenergetics | Knockout and overexpression models to study autophagy and mitochondrial function |
| STARD1 (STAR) | START domain protein mediating cholesterol trafficking in steroidogenic cells | Knockout and knock-in models for steroidogenesis |
| STARD3 | START domain protein involved in intracellular cholesterol movement | Studies of endosomal cholesterol transport |
| STARD4 | START domain protein implicated in cholesterol transfer | Live-cell imaging of cholesterol dynamics |
| STARD5 | START domain protein linked to cholesterol and bile acid metabolism | Metabolic disease models |
| STARD6 | START domain protein expressed in steroidogenic tissues | Reproductive biology studies |
| ANXA1 | Annexin family protein with membrane and mitochondrial roles | Membrane dynamics and cholesterol-related studies |
| ANXA2 | Annexin family protein involved in membrane organization | Caveolae and membrane signaling studies |
| ANXA5 | Annexin family protein with calcium-dependent membrane binding | Membrane repair and lipid transport studies |
| CAV1 | Caveolae structural protein regulating eNOS and cholesterol-rich domains | Caveolae signaling and cholesterol transport models |
| CAV2 | Caveolae component cooperating with CAV1 | Membrane microdomain research |
| SREBF1 | Transcription factor controlling lipogenic gene expression | SREBP activation studies |
| SREBF2 | Transcription factor controlling cholesterol synthesis and uptake genes | Sterol metabolism research |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis | Feedback regulation studies |
| NPC1 | Endosomal cholesterol export protein | Cholesterol trafficking and disease models |
| NPC2 | Lysosomal cholesterol transfer protein | Intracellular cholesterol transport research |
| ABCA1 | Cholesterol efflux transporter | Membrane cholesterol regulation studies |
How Is negative regulation of intracellular cholesterol transport Regulated?
Negative regulation of intracellular cholesterol transport is controlled by feedback sensing of active cholesterol at the plasma membrane, which coordinates cell cholesterol homeostasis. SREBP activation responds to sterol levels and adjusts expression of cholesterol synthesis and uptake genes, indirectly influencing transport rates. Phosphatidylcholine availability modulates the cholesterol transport machinery, adding a lipid-composition layer of control. GRAMD1C links cholesterol transport to autophagy initiation and mitochondrial bioenergetics, providing a regulatory node between lipid trafficking and organelle quality control.
negative regulation of intracellular cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRAMD1C | Autophagy and mitochondrial bioenergetics in cancer and metabolic disease | Knockout and overexpression cell models |
| NPC1 | Niemann-Pick type C disease and lysosomal cholesterol storage | Patient-derived fibroblasts and knock-in models |
| NPC2 | Niemann-Pick type C disease | Knockout and complementation models |
| STARD1 | Steroidogenic disorders and lipoid congenital adrenal hyperplasia | Knockout and knock-in steroidogenic cell models |
| CAV1 | Endothelial dysfunction and cardiovascular disease | Endothelial cell knockout and overexpression models |
Cancer and metabolic reprogramming
Altered cholesterol trafficking supports rapid membrane synthesis and signaling in cancer cells. Negative regulation of intracellular cholesterol transport can limit cholesterol availability for proliferation and may influence autophagy-dependent survival pathways through GRAMD1C.
Neurodegeneration and lysosomal cholesterol storage
Defects in intracellular cholesterol transport contribute to lysosomal storage disorders and neurodegeneration. Active cholesterol sensing and NPC1/NPC2-dependent pathways are central to maintaining neuronal cholesterol balance.
Cardiovascular and endothelial dysfunction
Caveolae-associated cholesterol transport regulates eNOS signaling in endothelial cells. Disruption of negative regulation of cholesterol movement can alter caveolae-dependent signaling and vascular function.
Steroidogenic and endocrine disorders
START domain proteins control cholesterol delivery for steroid hormone synthesis. Impaired negative regulation of this trafficking can affect adrenal and gonadal steroid production.
From negative regulation of intracellular cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GRAMD1C alter autophagosome biogenesis? | GRAMD1C knockout cell line |
| Does a point mutation in a START domain change cholesterol transfer? | Point-mutation knock-in cell model |
| Can a tagged transport protein be tracked in live cells? | Tagged knock-in of STARD or GRAMD1 family member |
| Does overexpression of a cholesterol transporter reduce mitochondrial cholesterol? | Overexpression cell model |
| Which genes modify negative regulation of cholesterol transport? | CRISPR library screening |
| How does phosphatidylcholine availability affect transport? | Lipid-manipulated knockout and overexpression models |
How to Study the negative regulation of intracellular cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Live-cell fluorescence imaging | Real-time cholesterol movement and organelle contact sites | Tracking transport protein dynamics |
| RNA-seq | Transcriptional changes in cholesterol and autophagy genes | SREBP and GRAMD1C pathway analysis |
| Lipidomics | Cholesterol and phospholipid species distribution | Membrane composition studies |
| Respirometry | Mitochondrial bioenergetics | GRAMD1C functional studies |
| Autophagy flux assays | Autophagosome formation and degradation | Cholesterol transport and autophagy crosstalk |
| CRISPR knockout screening | Gene requirements for cholesterol transport regulation | Pathway discovery |
| Proteomics | Protein interactions of transport machinery | START domain and annexin complexes |
| Immunofluorescence | Subcellular localization of transport proteins | Organelle-specific cholesterol studies |
Live-cell cholesterol imaging
Fluorescent cholesterol probes and tagged transport proteins allow real-time tracking of cholesterol movement between membranes. These approaches can reveal how negative regulation slows specific transport steps.
Transcriptomic and lipidomic profiling
RNA-seq and lipidomics measure changes in cholesterol synthesis, uptake, and storage genes after manipulating transport regulators such as GRAMD1C or SREBP pathway components.
Autophagy and mitochondrial function assays
Autophagosome biogenesis and mitochondrial bioenergetics can be assessed by imaging, flux analysis, and respirometry in cells with altered cholesterol transport.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens combined with pathway enrichment can identify modifiers of intracellular cholesterol transport and its negative regulation.
How CRISPR Can Be Used to Study GO:0032384 negative regulation of intracellular cholesterol transport
Knockout
CRISPR knockout of GRAMD1C, START domain genes, or NPC1 can reveal loss-of-function effects on cholesterol distribution, autophagy, and mitochondrial function.
Point Mutation
Point mutations in cholesterol-binding or transfer domains of START proteins and GRAMD1C can dissect which residues are required for negative regulation of transport.
Knock-in
Tagged knock-in of transport proteins enables live-cell imaging and proteomic analysis of cholesterol transport complexes without overexpression artifacts.
Overexpression
Overexpression of cholesterol transporters or dominant-negative regulators can test whether increased transport overrides negative regulation and alters organelle function.
How EDITGENE Supports negative regulation of intracellular cholesterol transport Research
Researchers studying negative regulation of intracellular cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in cholesterol movement, organelle function, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that allow precise manipulation of these genes in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of intracellular cholesterol transport research.
Frequently Asked Questions About negative regulation of intracellular cholesterol transport
What is GO:0032384?
GO:0032384 is the Gene Ontology term for negative regulation of intracellular cholesterol transport, defined as any process that stops, prevents, or reduces the directed movement of cholesterol within cells.
What does negative regulation of intracellular cholesterol transport mean?
It means cellular mechanisms that slow or block the movement of cholesterol between membranes and organelles, helping maintain cholesterol homeostasis.
What genes are involved in negative regulation of intracellular cholesterol transport?
Genes include GRAMD1C, START domain proteins such as STARD1 and STARD3, annexins, caveolae proteins, and SREBP pathway components.
How is intracellular cholesterol transport regulated?
It is regulated by active cholesterol sensing at the plasma membrane, SREBP feedback, phosphatidylcholine availability, and proteins such as GRAMD1C.
Why is negative regulation of cholesterol transport important in disease?
Dysregulation contributes to cancer metabolism, neurodegeneration, lysosomal storage disorders, cardiovascular dysfunction, and steroidogenic disorders.
What is the role of GRAMD1C in cholesterol transport?
GRAMD1C is a cholesterol transport protein that regulates autophagosome biogenesis and mitochondrial bioenergetics.
How can I study negative regulation of intracellular cholesterol transport?
Use live-cell imaging, lipidomics, RNA-seq, autophagy flux assays, and CRISPR knockout or overexpression models.
What are START domain proteins?
START domain proteins mediate intracellular cholesterol trafficking, especially in steroidogenic cells, and are targets of negative regulation.
Does phosphatidylcholine affect cholesterol transport?
Yes, phosphatidylcholine availability influences the cholesterol transport machinery and membrane properties.
How does SREBP relate to cholesterol transport?
SREBP activation responds to sterol levels and adjusts expression of cholesterol synthesis and uptake genes, indirectly affecting transport.
Conclusion
GO:0032384, negative regulation of intracellular cholesterol transport, is a critical biological process that maintains cholesterol distribution and organelle function. Key proteins such as GRAMD1C and START domain proteins, together with lipid signals like active cholesterol and phosphatidylcholine, coordinate this negative regulation. Dysregulation is linked to cancer, neurodegeneration, cardiovascular disease, and endocrine disorders, making it an important area for CRISPR-based functional studies.
References
- 1. Lange Y et al.. 2024. How active cholesterol coordinates cell cholesterol homeostasis: Test of a hypothesis.. Prog Lipid Res 96:101304 PMID: 39491591
- 2. Charsou C et al.. 2023. Regulation of autophagosome biogenesis and mitochondrial bioenergetics by the cholesterol transport protein GRAMD1C.. Autophagy 19(7):2159-2161 PMID: 36469687
- 3. Bandorowicz-Pikuła J et al.. 2016. [Annexins in mitochondria].. Postepy Biochem 62(2):216-223 PMID: 28132474
- 4. Strauss JF 3rd et al.. 2003. START domain proteins and the intracellular trafficking of cholesterol in steroidogenic cells.. Mol Cell Endocrinol 202(1-2):59-65 PMID: 12770731
- 5. Lagace TA. 2015. Phosphatidylcholine: Greasing the Cholesterol Transport Machinery.. Lipid Insights 8(Suppl 1):65-73 PMID: 27081313
- 6. Mineo C et al.. 2012. Regulation of eNOS in caveolae.. Adv Exp Med Biol 729:51-62 PMID: 22411313
- 7. Sato R. 2010. Sterol metabolism and SREBP activation.. Arch Biochem Biophys 501(2):177-81 PMID: 20541520
- 8. Ng MYW et al.. 2022. The cholesterol transport protein GRAMD1C regulates autophagy initiation and mitochondrial bioenergetics.. Nat Commun 13(1):6283 PMID: 36270994
